Last reviewed · How we verify
NCT04388371
Glutamine PET Imaging in LAM
Phase 1 trial testing Glutamine in Lymphangioleiomyomatosis (LAM) in 5 participants. Completed in 10 August 2021.
30 June 2021
Quick facts
| Lead sponsor | Vanderbilt University Medical Center |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 5 |
| Start date | 18 October 2019 |
| Primary completion | 30 June 2021 |
| Estimated completion | 10 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Glutamine (GLUTAMINE) — full drug profile →
Conditions studied
- Lymphangioleiomyomatosis (LAM) — all drugs for Lymphangioleiomyomatosis (LAM) →
Sponsor
Vanderbilt University Medical Center
Who can join
18 and older, female only, with Lymphangioleiomyomatosis (LAM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, subjects with spontaneous or tuberous sclerosis complex associated lymphangioleiomyomatosis (LAM) who have not been started on therapy with mTOR inhibitors such as sirolimus or everolimus to undergo a PET/CT scan using an novel PET tracer that may better evaluate disease activity in LAM subjects both before and after the initiation of mTOR inhibitor therapy will be enrolled. The procedure for each scan will be similar, involving one administration of the novel tracer C11-glutamine followed by a whole body PET/CT scan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04388371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Glutamine
Trials testing the same drug.
- NCT06617182 — Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. · Phase 2 · recruiting
- NCT05655819 — A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia · Phase 1, PHASE2 · completed
- NCT05569993 — Glutamine and Traumatic Brain Injury · EARLY_PHASE1 · unknown
- NCT05856188 — Efficacy of Glutamine in Management of Radiation Mucositis · NA · unknown
- NCT04909905 — Glutamine Supplementation and Short-term Mortality in Covid-19 · Phase 3 · completed
Other recruiting trials for Lymphangioleiomyomatosis (LAM)
Currently open trials in the same condition.
- NCT07304856 — Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tube · recruiting
Other Vanderbilt University Medical Center trials
Trials by the same sponsor.
- NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
- NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
- NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
- NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
- NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04388371 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
- Last refreshed: 11 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04388371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing